Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283761 | 0.89 | ALDH1A1 (0.54) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL3156353 | 0.86 | GPR119 (0.49) | ALDH1A1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3164585 | 0.85 | GPR119 (0.51) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3165672 | 0.84 | MEN1 (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3160552 | 0.84 | GPR119 (0.54) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3151575 | 0.84 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL4274190 | 0.84 | PDE4B (0.46) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL3165435 | 0.83 | PDE4B (0.54) | ALDH1A1HTTPDE4BPDE4DPDE4A | |
| SCHEMBL3163770 | 0.83 | GPR119 (0.49) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3156761 | 0.83 | GPR119 (0.54) | PDE4BPDE4DPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | NPC1 1622/4885ALDH1A1 715/4885MAPT 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.